To study the adaptive changes during targeted inhibition of oncogenic signaling we exposed cancer cells (n = 9) driven by diverse activated kinases (EGFR, MET, BRAF, HER2, ALK) to targeted drugs and performed transcriptional profiling using RNA-seq (Supplementary Fig. 1a). The gene discussed is ERBB2; the disease is cancer.